3
Mar
2017

Grail’s $900M Haul, Kite’s CAR-T Stands Up 6 Months, & Icahn Returns

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround
FDA Gutted, Novartis Kidney Drug Pays Off, and Isomorphic Raises a Fortune
A Moment of Peril and Promise
Curevo and Arbor Defy Gravity, Cargo Hits the Wall, & AZ Bets on In Vivo